FDA Approval Alert: The Need-to-Know | Adjuvant Durvalumab/Chemotherapy in Muscle-Invasive Bladder Cancer

In March 2025, the FDA approved durvalumab plus chemotherapy followed by single-agent durvalumab for patients with muscle-invasive bladder cancer after radical cystectomy.

FDA Approves Adjuvant Durvalumab/Chemo in Muscle-Invasive Bladder Cancer
FDA Approves Adjuvant Durvalumab/Chemo in Muscle-Invasive Bladder Cancer
Article
Mar 28, 2025 8:28 PM
Results from the phase 3 NIAGARA trial led to the approval of adjuvant durvalumab/chemotherapy for patients with muscle-invasive bladder cancer after radical cystectomy.